Konstantinos Xynos
Fortune : 3 M $ au 31/07/2026
Fortune : 3 M $ au 31/07/2026
Konstantinos Xynos is Chief Medical Officer at Replimune Group, Inc. since 2022.
Formerly, Dr. Xynos was Vice President & Head-Global Medical Affairs at Deciphera Pharmaceuticals, Inc. from 2019 to 2021.
Education includes an undergraduate degree from the University of Illinois (1991), a doctorate from Aristotle University of Thessaloniki (1997), a doctorate from National & Kapodistrian University of Athens (2012), and an MBA from the University of Strathclyde (2013).
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. 0,29 % | 10/08/2026 | 224 215 ( 0,29 % ) | 3 M $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| REPLIMUNE GROUP, INC. | Directeur Technique/Scientifique/R&D | 01/12/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2021 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristotle University of Thessaloniki
Aristotle University of Thessaloniki Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National & Kapodistrian University of Athens
National & Kapodistrian University of Athens Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national